<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Adult, de novo B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> meeting the WHO morphologic criteria for atypical Burkitt/Burkitt-like <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cause diagnostic difficulty for pathologists because the genetic and clinical characteristics of this group of <z:hpo ids='HP_0002665'>lymphomas</z:hpo> have not been clearly defined </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty-one such <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, designated as Burkitt-like <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e>), were selected based on morphologic features and evaluated for immunophenotype, MYC and BCL2 status, and clinical features </plain></SENT>
<SENT sid="2" pm="."><plain>Nine childhood Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and 87 adult, de novo diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (DLBL) were similarly evaluated for comparison </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> group demonstrated uniform characteristics: <z:hpo ids='HP_0000001'>all</z:hpo> had Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> <z:mp ids='MP_0000002'>morphology</z:mp>, an identical immunophenotype (positive for CD20, CD10, bcl-6, CD43, and p53; negative for CD138, CD23, bcl-2), high MIB-1 positivity, IGH/MYC translocation, no IGH/BCL2 translocation, and <z:hpo ids='HP_0000001'>all</z:hpo> patients were alive at the last follow-up </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> and DLBL groups were <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Burkitt-like <z:mp ids='MP_0000002'>morphology</z:mp> alone correlated with decreased survival </plain></SENT>
<SENT sid="6" pm="."><plain>IGH/MYC or IGL/MYC fusion was identified in 11 of 27 (41%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> and 4 of 76 (5%) DLBL and was associated with decreased survival in both groups </plain></SENT>
<SENT sid="7" pm="."><plain>MIB-1 positivity did not correlate with <z:mp ids='MP_0000002'>morphology</z:mp>, MYC abnormalities, or survival </plain></SENT>
<SENT sid="8" pm="."><plain>We propose that adult B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> <z:mp ids='MP_0000002'>morphology</z:mp> are a phenotypically and genetically <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of aggressive <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, biologically distinct from childhood <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Until biologically accurate subgroups within this morphologically defined group are identified, it is appears that both recognition of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> <z:mp ids='MP_0000002'>morphology</z:mp> and direct evaluation for the presence of MYC fusion to immunoglobulin genes are important for identification of adult patients with poorer prognosis than those with DLBL </plain></SENT>
</text></document>